#1 Clinical Trials Search in Europe

Ep262

EP262 is a promising new drug currently undergoing clinical trials for various skin conditions, including chronic inducible urticaria, chronic spontaneous urticaria, and atopic dermatitis. These trials aim to evaluate the safety, tolerability, and effectiveness of EP262 in treating these challenging skin disorders. The studies range from early-phase investigations to more advanced placebo-controlled trials, offering hope for patients seeking new treatment options.

Table of Contents

What is EP262?

EP262 is a new drug that is currently being studied for its potential to treat various skin conditions[1]. It is an oral medication, which means it is taken by mouth, usually once daily[2]. The drug is still in the experimental stage and is being tested in several clinical trials to determine its effectiveness and safety.

What Conditions Does EP262 Treat?

Based on the ongoing clinical trials, EP262 is being investigated for the treatment of several skin conditions:

  • Chronic Spontaneous Urticaria (CSU): This is a condition where itchy, red welts (hives) appear on the skin for no apparent reason and last for more than six weeks[2].
  • Chronic Inducible Urticaria (CIndU): This type of urticaria is triggered by specific stimuli, such as pressure or cold. Two subtypes being studied are:
    • Symptomatic dermographism: Where hives appear after the skin is scratched or rubbed
    • Cold urticaria: Where hives develop after exposure to cold temperatures[3]
  • Atopic Dermatitis: Also known as eczema, this is a chronic condition that causes dry, itchy, and inflamed skin[4].

How EP262 Works

While the exact mechanism of action is not explicitly stated in the clinical trial information, we can infer some details about how EP262 might work:

  • For urticaria (hives), EP262 appears to target the underlying causes of itching and hive formation. It may help reduce the intensity of itching and the number of hives that appear on the skin[2].
  • In cases of chronic inducible urticaria, EP262 might help increase the threshold at which symptoms appear. This means that patients may be able to tolerate more friction on their skin or colder temperatures before developing hives[3].
  • For atopic dermatitis, EP262 may work by affecting the skin’s immune response and inflammation. The drug’s effects on skin thickness and immune cell presence are being studied, which suggests it may help normalize the skin’s structure and reduce inflammation[4].

Clinical Trials for EP262

EP262 is currently being studied in several clinical trials:

  1. Phase 1 Study in Healthy Males: This study is looking at how EP262 is absorbed, processed, and eliminated by the body. It uses a special form of the drug labeled with a radioactive marker to track its movement through the body[1].
  2. Phase 2 Study in Chronic Spontaneous Urticaria: This larger study is testing EP262 against a placebo in patients with chronic spontaneous urticaria. It aims to see if the drug can reduce symptoms like itching and hives[2].
  3. Phase 1b Study in Chronic Inducible Urticaria: This study is focusing on patients with specific types of urticaria triggered by friction or cold. It will test how EP262 affects patients’ sensitivity to these triggers[3].
  4. Phase 2a Study in Atopic Dermatitis: This study is examining how EP262 affects the skin of patients with atopic dermatitis, including changes in skin structure and gene expression[4].

Safety and Side Effects

As EP262 is still in clinical trials, its full safety profile is not yet known. However, all the ongoing studies are closely monitoring for any side effects or safety concerns. The researchers are looking at several aspects of safety:

  • Treatment-emergent adverse events (side effects that appear or worsen after starting the medication)
  • Changes in laboratory test results
  • Effects on vital signs
  • Changes in electrocardiogram (ECG) readings
  • Findings from physical examinations[1][2][3][4]

It’s important to note that all new drugs must pass rigorous safety testing before they can be approved for general use.

Future Prospects for EP262

The ongoing clinical trials for EP262 suggest that this drug has potential in treating several challenging skin conditions. If the results of these studies are positive, EP262 could become a valuable new treatment option for patients with chronic urticaria and atopic dermatitis.

However, it’s important to remember that drug development is a long and complex process. Even if these initial studies show promising results, more research will be needed to fully understand the effectiveness and safety of EP262 before it can be made available to the public.

Patients with these conditions should continue to work closely with their healthcare providers and stay informed about new developments in treatment options.

Trial Phase Condition Primary Outcomes Key Secondary Outcomes
Phase 1 Healthy Participants Mass balance, Pharmacokinetics of EP262 Metabolite profile, Safety and tolerability
Phase 1b Chronic Inducible Urticaria Safety and tolerability Change in Critical Friction Threshold, Change in Critical Temperature Threshold
Phase 2 Chronic Spontaneous Urticaria Change in Urticaria Activity Score (UAS7) Safety and tolerability, Change in Itch Severity Score (ISS7), Change in Hive Severity Score (HSS7)
Phase 2a Atopic Dermatitis Safety and tolerability Effect on skin histology, Effect on skin gene expression

FAQ

  • What is EP262? EP262 is an investigational drug being studied for its potential to treat various skin conditions, including different types of urticaria (hives) and atopic dermatitis (eczema). It is taken orally, usually once daily.
  • What conditions is EP262 being tested for? EP262 is currently being tested in clinical trials for chronic inducible urticaria, chronic spontaneous urticaria, and atopic dermatitis. These are all skin conditions that can cause significant discomfort and impact quality of life.
  • How is EP262 administered? In the clinical trials, EP262 is administered orally, typically once daily. The exact dosage may vary depending on the specific trial and condition being studied.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety and tolerability of EP262, assess its effectiveness in reducing symptoms of the targeted skin conditions, and understand how the drug is absorbed, metabolized, and excreted by the body.
  • How long do these clinical trials last? The duration of the trials varies, but they generally last between 1 to 3 months. Some trials may have follow-up periods that extend the total study time.

Ongoing Clinical Trials on Ep262

  • Study on the Effects of EP262 for Adults with Chronic Spontaneous Urticaria

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Poland Spain

Glossary

  • Chronic Inducible Urticaria (CIndU): A type of urticaria (hives) that occurs in response to specific triggers, such as friction on the skin or exposure to cold temperatures.
  • Chronic Spontaneous Urticaria (CSU): A condition characterized by the recurring appearance of hives and/or angioedema for more than six weeks, without an identifiable external trigger.
  • Atopic Dermatitis: A chronic inflammatory skin condition, also known as eczema, characterized by dry, itchy, and inflamed skin.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Mass Balance: A method used to track the absorption, distribution, metabolism, and excretion of a drug in the body using radioactive labeling.
  • Urticaria Activity Score (UAS): A tool used to measure the severity of urticaria symptoms, including the intensity of itch and the number of hives.
  • Critical Friction Threshold (CFT): The minimum amount of friction required to elicit a wheal (raised, itchy area on the skin) in patients with symptomatic dermographism.
  • Critical Temperature Threshold (CTT): The highest temperature that triggers a wheal response in patients with cold urticaria.
  • Treatment-Emergent Adverse Events: Any unfavorable or unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.

References

  1. https://clinicaltrials.gov/study/NCT06645704
  2. https://clinicaltrials.gov/study/NCT06077773
  3. https://clinicaltrials.gov/study/NCT06050928
  4. https://clinicaltrials.gov/study/NCT06144424